Literature DB >> 3556291

Chronic administration of theophylline to rats induces a post-insulin binding defect in adipocyte glucose transport.

A Green.   

Abstract

To determine whether adenosine is involved in long-term regulation of glucose transport in adipose tissue, we have investigated effects of administration of an adenosine receptor antagonist (theophylline) on adipocyte glucose transport. Rats were injected with theophylline (30 mg/kg, dissolved in 0.9% NaCl) daily for 7 days. Controls were injected with saline. The rats were then killed, and epididymal adipocytes were isolated. Insulin-stimulated glucose transport rates were decreased by about 25%-30% in the cells from theophylline-treated rats at all insulin concentrations tested. The half-maximally effective concentration of insulin was not altered (6.5 +/- 0.5 and 6.7 +/- 0.5 mU/l in control and treated cells respectively), suggesting a post-insulin binding defect. This was confirmed by the finding that 125I-insulin binding to the cells was not altered. Adenosine receptor number and affinity (measured on detergent-solubilized adipocyte extracts using 125I-hydroxyphenylisopropyl adenosine) was also not changed by theophylline treatment. We conclude that theophylline administration causes decreased glucose transport rates in rat adipocytes at a post-insulin binding level. Thus, chronic adenosine receptor blockade impairs adipocyte glucose transport, suggesting that adenosine is involved in long-term regulation of glucose metabolism in adipose tissue.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3556291     DOI: 10.1007/BF00274226

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  31 in total

1.  A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.

Authors:  K BURTON
Journal:  Biochem J       Date:  1956-02       Impact factor: 3.857

2.  Effects of streptozotocin-induced diabetes on insulin binding, glucose transport, and intracellular glucose metabolism in isolated rat adipocytes.

Authors:  M Kobayashi; J M Olefsky
Journal:  Diabetes       Date:  1979-02       Impact factor: 9.461

3.  Adenosine release from fat cells: effect on cyclic AMP levels and hormone actions.

Authors:  U Schwabe; R Ebert; H C Erbler
Journal:  Adv Cyclic Nucleotide Res       Date:  1975

4.  Facilitation by adenosine of the action of insulin on the accumulation of adenosine 3':5'-monophosphate, lipolysis, and glucose oxidation in isolated fat cells.

Authors:  U Schwabe; P S Schönhöfer; R Ebert
Journal:  Eur J Biochem       Date:  1974-08-01

5.  Adenosine release from isolated fat cells and its significance for the effects of hormones on cyclic 3',5'-AMP levels and lipolysis.

Authors:  U Schwabe; R Ebert; H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

6.  Adenosine receptors and the regulation of adenylate cyclase.

Authors:  J Wolff; C Londos; D M Cooper
Journal:  Adv Cyclic Nucleotide Res       Date:  1981

7.  Mechanisms of the ability of insulin to activate the glucose-transport system in rat adipocytes.

Authors:  J M Olefsky
Journal:  Biochem J       Date:  1978-04-15       Impact factor: 3.857

8.  Long-term regulation of adipocyte glucose transport capacity by circulating insulin in rats.

Authors:  M Kobayashi; J M Olefsky
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

9.  Adenosine actions and adenosine receptors after 1 week treatment with caffeine.

Authors:  B B Fredholm
Journal:  Acta Physiol Scand       Date:  1982-06

10.  Glucagon inhibition of insulin-stimulated 2-deoxyglucose uptake by rat adipocytes in the presence of adenosine deaminase.

Authors:  A Green
Journal:  Biochem J       Date:  1983-04-15       Impact factor: 3.857

View more
  1 in total

1.  Caffeine's impairment of insulin-mediated glucose disposal cannot be solely attributed to adrenaline in humans.

Authors:  D S Battram; T E Graham; F Dela
Journal:  J Physiol       Date:  2007-07-26       Impact factor: 5.182

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.